Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49:1700214.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med. 2014;35:191–201.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188:901–906.
   PubMed Web of Science ®Google Scholar
• Olsson B, Bondesson E, Borgström L, et al. Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey AJ, editors. Controlled Pulmonary drug delivery. New York, NY: Springer; 2011. p. 21–50.
   Google Scholar
• Turfus SC, Delgoda R, Picking D, et al. Pharmacokinetics. In: Badal S, Delgoda R, editors. Pharmacognosy: fundamentals, applications and strategies. London, UK: Academic Press; 2017. p. 495–512.
   Google Scholar
• Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42:697–705.
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588–599.
   PubMed Web of Science ®Google Scholar
• Bäckström E, Boger E, Lundqvist A, et al. Lung retention by lysosomal trapping of inhaled drugs can be predicted in vitro with lung slices. J Pharm Sci. 2016;105:3432–3439.
   PubMed Web of Science ®Google Scholar
• Upton RN, Doolette DJ. Kinetic aspects of drug disposition in the lungs. Clin Exp Pharmacol Physiol. 1999;26:381–391.
   PubMed Web of Science ®Google Scholar
• Wanner A. Clinical perspectives: role of the airway circulation in drug therapy. J Aerosol Med. 1996;9:19–23.
   PubMedGoogle Scholar
• International Commission on Radiological Protection ICRP Publication 66. Human respiratory tract model for radiological protection. New York, NY: Elsevier; 1994. Available from: www.icrp.org/publication.asp?id=icrp%20publication%2066
   Google Scholar
• Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41:19–30.
   PubMed Web of Science ®Google Scholar
• Corcoran TE. Imaging in aerosol medicine. Respir Care. 2015;60(6):850–855.
   PubMed Web of Science ®Google Scholar
• Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol. 1992;34(4):311–315.
   PubMed Web of Science ®Google Scholar
• Clark DJ, Tan KS, Lipworth BJ. Evaluation of plasma and urinary salbutamol levels in COPD. Eur J Clin Pharmacol. 1996;51:91–93.
   PubMed Web of Science ®Google Scholar
• Taburet AM, Tollier C, Richard C. The effect of respiratory disorders on clinical pharmacokinetic variables. Clin Pharmacokinet. 1990;19:462–490.
   PubMed Web of Science ®Google Scholar
• Kim CS, Kang TC. Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Am J Respir Crit Care Med. 1997;155:899–905.
   PubMed Web of Science ®Google Scholar
• Sweeney TD, Skornik WA, Brain JD, et al. Chronic bronchitis alters the pattern of aerosol deposition in the lung. Am J Respir Crit Care Med. 1995;151:482–488.
   PubMed Web of Science ®Google Scholar
• Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25:140–147.
   PubMed Web of Science ®Google Scholar
• Smaldone GC, Messina MS. Flow limitation, cough and patterns of aerosol deposition in humans. J Appl Physiol. 1985;59:515–520.
   PubMed Web of Science ®Google Scholar
• Sweeney TD, Brain JD, Leavitt SA, et al. Emphysema alters the deposition pattern of inhaled particles in hamsters. Am J Pathol. 1987;128:19–28.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Bettoncelli G, et al. The prevalence of asthma and COPD in Italy: a practice-based study. Respir Med. 2011;105:386–391.
   PubMed Web of Science ®Google Scholar
• Wallin M, Tagami T, Chen L, et al. Pulmonary drug delivery to older people. Adv Drug Deliv Rev. 2017.
   PubMed Web of Science ®Google Scholar
• Wang YB, Watts AB, Peters JI, et al. The impact of pulmonary diseases on the fate of inhaled medicines—A review. Int J Pharm. 2014;461(1–2):112–128.
   PubMed Web of Science ®Google Scholar
• Duarte AG, Dhand R, Reid R, et al. Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1658–1663.
   PubMed Web of Science ®Google Scholar
• Duarte AG. Inhaled bronchodilator administration during mechanical ventilation. Respir Care. 2004;49(6):623–634.
   PubMedGoogle Scholar
• Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017;124:6–14.
   PubMed Web of Science ®Google Scholar
• Brunnée T, Engelstätter R, Steinijans VW, et al. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J. 1992;5:982–985.
   PubMed Web of Science ®Google Scholar
• Morgan DJ. Clinical pharmacokinetics of β-agonists. Clin Pharmacokinet. 1990;18:270–294.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Rodrigo C. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels. Am J Emerg Med. 1996;14(2):144–150.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Mehta R, Chan RH, et al. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. J Aerosol Med Pulm Drug Deliv. 2014;27(4):279–289.
   PubMed Web of Science ®Google Scholar
• Gross NJ, Kerwin E, Levine B, et al. Nebulized formoterol fumarate: dose selection and pharmacokinetics. Pulm Pharmacol Ther. 2008;21:818–823.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page CP, et al. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014;10:129–137.
   PubMed Web of Science ®Google Scholar
• van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666–672.
   PubMed Web of Science ®Google Scholar
• Häussermann S, Acerbi D, Brand P, et al. Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med. 2007;20:331–341.
   PubMedGoogle Scholar
• Darquenne C. Aerosol deposition in the human lung in reduced gravity. J Aerosol Med Pulm Drug Deliv. 2014;27(3):170–177.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med. 2010;104:1869–1876.
   PubMed Web of Science ®Google Scholar
• Novartis. Interview form: onbrez inhalation capsules (drug information about indacaterol maleate) (Japanese). 2015. [Cited 2018 Sep 02]. Available from: https://drs-net.novartis.co.jp/siteassets/common/pdf/onb/if/if_onb.pdf
   Google Scholar
• Feldman G, Walker RR, Brooks J, et al. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25:465–471.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26:256–264.
   PubMed Web of Science ®Google Scholar
• Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2014;75(1):61–74.
   Web of Science ®Google Scholar
• Goyal N, Beerahee M, Kalberg C, et al. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 2014;53:637–648.
   PubMed Web of Science ®Google Scholar
• Ingelheim B. Product monograph. striverdi respimat (olodaterol hydrochloride inhalation solution). [Cited 2018 Sep 14]. Available from: https://www.boehringer-ingelheim.ca/sites/ca/files/documents/striverdipmen.pdf
   Google Scholar
• Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64:457–464.
   PubMed Web of Science ®Google Scholar
• Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3:247–268.
   PubMedGoogle Scholar
• Price D, Sharma A, Cerasoli F. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin Drug Metab Toxicol. 2009;5:417–424.
   PubMed Web of Science ®Google Scholar
• Ingelheim B. Interview form: spiriva Respimat (drug information about tiotropium bromide hydrate) (Japanese). 2017. [Cited 2018 Sep 14]. Available from: http://www.info.pmda.go.jp/go/pack/2259709G1027_1_14/
   Google Scholar
• Disse B, Rominger K, Serby CW, et al. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD [abstract]. Am J Respir Crit Care Med. 1999;159(Suppl. Pt 2):A524.
   Google Scholar
• Hohlfeld J, Sharma A, van Noord J, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54:405–414.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26:307–317.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2014;15:961–977.
   PubMed Web of Science ®Google Scholar
• Jansat JM, Lamarca R, de Miquel G, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participant. J Clin Pharmacol. 2009;49:1239–1246.
   PubMed Web of Science ®Google Scholar
• Lasseter K, Dilzer S, Jansat JM, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther. 2012;25:193–199.
   PubMed Web of Science ®Google Scholar
• de la Motte S, Beier J, Schmid K, et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther. 2012;50:403–412.
   PubMed Web of Science ®Google Scholar
• Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73:741–753.
   PubMed Web of Science ®Google Scholar
• Bartels C, Looby M, Sechaud R, et al. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol. 2013;76:868–879.
   PubMed Web of Science ®Google Scholar
• Sechaud R, Ranard D, Zhang-Auberson L, et al. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50:118–128.
   PubMed Web of Science ®Google Scholar
• Rennard S, Fogarty C, Reisner C, et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:118.
   PubMed Web of Science ®Google Scholar
• Cahn A, Lovick R, Newlands A, et al. Safety, tolerability, pharmacodynamics (PD) and pharmocokinetics (PK) of GSK573719 inhalation powder in healthy subjects. Eur Respir J. 2011;38(Suppl. 55):723s.
   Google Scholar
• Mehta R, Hardes K, Cahn A, et al. Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults. Eur Respir J. 2011;38(Suppl. 55):723s.
   Google Scholar
• Hu C, Jia J, Dong K, et al. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial. PLoS One. 2015;10:e0121264.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Anzueto A, Brooks J, et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106:970–979.
   PubMed Web of Science ®Google Scholar
• Trivedi R, Richard N, Mehta R. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43:72–81.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Rogliani P, et al. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Rev Respir Med. 2018;12:261–264.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95–103.
   PubMed Web of Science ®Google Scholar
• Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012;7:E50716.
   PubMedGoogle Scholar
• Dhillon S. Tiotropium/olodaterol: a Review in COPD. Drugs. 2016;76:135–146.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Spiolto Respimat (tiotropium bromide and olodaterol): summary of product characteristics. 2015. [Cited 2018 Sep 14]. Available from: http://mri.medagencies.org/Human/Product/Details/44258
   Google Scholar
• Fuhr R, Leselbaum A, Aubets J. Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: a phase 1, open-label, single-dose study. Clin Pharmacol Drug Dev. 2016;5:109–117.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Watz H, Kretschmar G, et al. Pharmakokinetik, Sicherheit und Aktivitat von formoterol verabreicht uber den Genuair Inhalator ® mit und ohne Aclidinium-Bromid [Abstract]. Pneumologie. 2011;65:V446.
   Google Scholar
• Fogarty C, Ortiz S. Pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination via pressair/genuair vs formoterol via foradil aerolizer in patients with moderate to severe COPD [abstract]. Chest. 2014;146:45A.
   Google Scholar
• European Medicines Agency. Ultibro Breezhaler: European Medicines Agency assessment report. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002679/WC500151257.pdf
   Google Scholar
• Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014;74:465–488.
   PubMed Web of Science ®Google Scholar
• Ren S, Sechaud R, Su Z, et al. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects. Int J Clin Pharmacol Ther. 2017;55:147–155.
   PubMed Web of Science ®Google Scholar
• Demin I, Bartels C, Graham G, et al. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients. Int J Clin Pharmacol Ther. 2016;54:405–415.
   PubMed Web of Science ®Google Scholar
• Marjason J, Orevillo CJ, St Rose E, et al. Assessment of safety and pharmacokinetic profile of a novel fixed combination of glycopyrrolate and formoterol HFA MDI in healthy volunteers [abstract]. Am J Respir Crit Care Med. 2010;181:A4455.
   Google Scholar
• Reisner C, Fabbri LM, Kerwin EM, et al. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ delivery technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respir Res. 2017;18:8.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rodriguez-Roisin R, Reisner C, et al. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:945–953.
   PubMed Web of Science ®Google Scholar
• Ogilvie RI. Clinical pharmacokinetics of theophylline. Clin Pharmacokinet. 1978;3:267–293.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc. 2005;2:334–339.
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P‐450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414–423.
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Brix TH, Kyvik KO, et al. The interindividual differences in the 3‐demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002;12:473–478.
   PubMedGoogle Scholar
• Ma YJ, Jiang DQ, Meng JX, et al. Theophylline: a review of population pharmacokinetic analyses. J Clin Pharm Ther. 2016;41:594–601.
   PubMed Web of Science ®Google Scholar
• Spina D, Page CP. Xanthines and phosphodiesterase inhibitors. Handb Exp Pharmacol. 2017;237:63–91.
   PubMedGoogle Scholar
• Bukowskyj M, Nakatsu K, Munt PW. Theophylline reassessed. Ann Intern Med. 1984;101:63–73.
   PubMed Web of Science ®Google Scholar
• Jenne H, Nagasawa H, McHugh R, et al. Decreased theophylline half-life in cigarette smokers. Life Sci. 1975;17:195–198.
   PubMed Web of Science ®Google Scholar
• Zevin S, Benowitz N. Drug interactions with tobacco smoking. Clin Pharmacokinet. 1999;36:425–438.
   PubMed Web of Science ®Google Scholar
• Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophylline disposition. Clin Pharmacol Ther. 1976;19(5 Pt 1):546–551.
   PubMedGoogle Scholar
• Powell JR, Vozeh S, Hopewell P, et al. Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. Am Rev Respir Dis. 1978;118:229–238.
   PubMed Web of Science ®Google Scholar
• Cusack BJ, Crowley JJ, Mercer GD, et al. Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. Am Rev Respir Dis. 1986;133:1110–1114.
   PubMed Web of Science ®Google Scholar
• Vallner JJ, Speir WA Jr, Kolbeck RC, et al. Effect of pH on the binding of theophylline to serum proteins. Am Rev Respir Dis. 1979;120(1):83–86.
   PubMedGoogle Scholar
• Resar RK, Walson PD, Fritz WL, et al. Kinetics of theophylline: variability and effect of arterial pH in chronic obstructive lung disease. Chest. 1979;76(1):11–16.
   PubMed Web of Science ®Google Scholar
• Zarowitz B, Shlom J, Eichenhorn MS, et al. Alterations in theophylline protein binding in acutely ill patients with COPD. Chest. 1985;87:766–769.
   PubMed Web of Science ®Google Scholar
• Richer M, Lam YW. Hypoxia, arterial pH and theophylline disposition. Clin Pharmacokinet. 1993;25:283–299.
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Cazzola M. Doxofylline is not just another theophylline! Int J Chron Obstruct Pulmon Dis. 2017;12:3487–3493.
   PubMed Web of Science ®Google Scholar
• Mennini FS, Sciattella P, Marcellusi A, et al. Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs theophylline. Expert Rev Pharmacoecon Outcomes Res. 2017;17:503–510.
   PubMed Web of Science ®Google Scholar
• Goldstein MF, Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma – a double-blind randomized placebo-controlled multicentre clinical trial. Med Sci Monit. 2002;8:CR297–CR304.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Barnes PJ, et al. Efficacy and safety profile of xanthines in COPD: a network meta-analysis. Eur Respir Rev. 2018;27:180010.
   PubMed Web of Science ®Google Scholar
• Patton JS, Brain JD, Davies LA, et al. The particle has landed - characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2):S71–S87.
   PubMed Web of Science ®Google Scholar
• Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers - therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1(5):402–413.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Questions & answers: positions on specific questions addressed to the pharmacokinetics working party (PKWP). [Cited 2018 Sep 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002963.pdf
   Google Scholar
• US Food and Drug Administration. FYs 2013–2017 Regulatory Science Report: Locally-Acting Orally Inhaled and Nasal Drug Products. Available from: https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/ucm592245.htm
   Google Scholar
• Al-Numani D, Colucci P, Ducharme MP. Rethinking bioequivalence and equivalence requirements of orally inhaled drug products. Ajps. 2015;10:461–471.
   Google Scholar
• Newman SP. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs? Br J Clin Pharmacol. 2000;49:529–537ù.
   PubMed Web of Science ®Google Scholar
• Nahar K, Gupta N, Gauvin R, et al. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci. 2013;49:805–818.
   PubMed Web of Science ®Google Scholar
• Zeitlinger M, Müller M, Joukhadar C. Lung microdialysis - A powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract. Aaps J. 2005;7:E600–E608.
   PubMed Web of Science ®Google Scholar
• Nilsson A, Fehniger TE, Gustavsson L, et al. Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PLoS One. 2010;5:e11411.
   PubMed Web of Science ®Google Scholar
• Fromer L, Goodwin E, Walsh J. Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med. 2010;122:83–93.
   PubMed Web of Science ®Google Scholar